Trials / Completed
CompletedNCT00241436
Open Label Arimidex in Gynecomastia
An Open-Label Pharmacokinetic and Pharmacodynamic Study of Anastrozole (Arimidex™) Used to Treat Pubertal Boys With Gynecomastia of Recent Onset
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 35 (planned)
- Sponsor
- AstraZeneca · Industry
- Sex
- Male
- Age
- 11 Years – 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety, effectiveness, pharmacokinetics and pharmacodynamics of anastrozole (ARIMIDEX™) in the treatment of boys with gynecomastia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Anastrozole (ARIMIDEX™) |
Timeline
- Start date
- 2005-06-01
- Primary completion
- 2006-11-01
- Completion
- 2006-11-01
- First posted
- 2005-10-19
- Last updated
- 2011-01-27
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00241436. Inclusion in this directory is not an endorsement.